Kinshasa / Paris / Geneva / Amsterdam — • Advice primarily based on Part II/III research demonstrating as much as 96 per cent success charges at 18 months throughout each early and superior phases of T.b. gambiense, the most typical kind of sleeping illness
• The remedy, given as a single dose of three tablets, might supply a less complicated various to longer, extra complicated regimens and assist assist the World Well being Group’s (WHO) objective of eliminating the illness by 2030
• Sanofi will donate the medication to WHO via its philanthropic arm Basis S
Comply with us on WhatsApp | LinkedIn for the newest headlines
The European Medicines Company’s Committee for Medicinal Merchandise for Human Use (CHMP) has granted a optimistic opinion to Acoziborole Winthrop (acoziborole) as a single-dose oral remedy for each early- and advanced-stage gambiense sleeping illness in adults in addition to in adolescents 12 years and older weighing at the least 40 kilograms.
A optimistic CHMP opinion via the EU-M4all process gives a powerful endorsement that the medication meets EU requirements. This pathway, which engages WHO illness consultants and regulators from endemic nations, is reserved for high-priority medicines addressing ailments with unmet medical wants. This choice will assist regulatory approval of the remedy within the Democratic Republic of Congo (DRC) and lay the groundwork for a revision of the WHO’s sleeping illness remedy tips. Such an replace would in the end broaden entry to the medication throughout different endemic nations in Central and West Africa.
As soon as authorized in endemic nations, the medication, co-developed by the Medication for Uncared for Illnesses initiative (DNDi) and Sanofi, might present a big advance over present therapies. Current therapies require both a 10-day course of oral drugs or a mixture of injections and oral remedy for superior circumstances.
‘In simply 20 years, now we have gone from sophisticated therapies together with arsenic derivatives with critical unwanted side effects, to at present, when a single-dose, one-day remedy might safely treatment sufferers,’ stated Dr Luis Pizarro, Govt Director at DNDi.
‘This progress is testomony to the transformative energy of collaborative science and can convey us nearer to lastly eliminating sleeping illness, a illness that has killed tens of millions on the African continent up to now century.’ Transmitted by the chew of an contaminated tsetse fly, human African trypanosomiasis, generally often known as sleeping illness, is nearly all the time deadly with out remedy. Within the early stage of the illness, individuals expertise complications or fever. Within the late stage, the parasite crosses the blood-brain barrier and invades the central nervous system, inflicting behavioural, cognitive, and neurological signs, together with seizures, sleep disturbance, aggression, confusion, lethargy, convulsions, and, in the end, demise.
DNDi performed a pivotal Part II/III research within the DRC and Guinea in partnership with nationwide sleeping illness management programmes, whereas Sanofi carried out the regulatory approval course of. The CHMP optimistic opinion is predicated on scientific and non-clinical information supplied by the companions, with efficacy and security supported by the Part II/III research, revealed in The Lancet Infectious Illnesses medical journal, which demonstrated success charges at 18 months of as much as 96 per cent throughout each phases of the illness with an excellent security profile.
‘The event of acoziborole and at present’s optimistic scientific opinion is a victory for Africa-led science, made potential due to African docs and researchers who performed cutting-edge pharmaceutical analysis in a few of the most distant and difficult-to-reach areas on the continent,’ stated Dr Erick Miaka, Director of the DRC’s nationwide sleeping illness management programme.
In 1998, practically 40,000 circumstances of gambiense sleeping illness have been reported, with an estimated 300,000 undiagnosed. On the time, the one out there remedy for these with the late stage of the illness was an injectable arsenic by-product with critical unwanted side effects. Greater than twenty years of funding in new therapeutic instruments resulted in more and more improved therapies, together with nifurtimox-eflornithine mixture remedy in 2009 and the primary oral remedy, fexinidazole, in 2018. In 2024, fewer than 600 circumstances of the illness have been reported. ‘For many years, Sanofi has maintained an unwavering dedication to the struggle in opposition to sleeping illness, standing alongside DNDi, the World Well being Group, and different companions in some of the enduring and profitable public-private well being collaborations,’ stated Audrey Duval, Govt Vice President, Company Affairs at Sanofi. ‘Collectively, now we have helped drive circumstances to historic lows— attaining a outstanding 98% discount since 2001—by placing sufferers first and investing in innovation the place it’s wanted most.
Acoziborole builds on this legacy and represents a decisive step ahead in eliminating gambiense sleeping illness by 2030.’ Sanofi will donate Acoziborole Winthrop to the WHO via its philanthropic group, Basis S – The Sanofi Collective. The drugs will probably be out there freed from cost to sufferers. One other research underway within the DRC and Guinea is investigating Acoziborole Winthrop for the remedy of kids ages 1 to 14.
Concerning the DNDi programme for the event of acoziborole
The DNDi programme for the event of acoziborole was supported by grants from the Federal Ministry of Analysis, Know-how and Area (BMFTR) via KfW, Germany; the BBVA Basis (via the ‘Frontiers of Information Award in Improvement Cooperation’); Dutch Ministry of International Affairs (DGIS), the Netherlands; European and Creating Nations Medical Trials Partnership Affiliation (EDCTP2 programme) supported by the European Union; World Well being EDCTP3 and its members; Gates Basis; Médecins Sans Frontières Worldwide; Norwegian Company for Improvement Cooperation (Norad), Norwegian Ministry of International Affairs, as a part of Norway’s in-kind contribution to EDCTP2; Swiss Company for Improvement and Cooperation (SDC); Swiss State Secretariat for Training, Analysis and Innovation (SERI); Stavros Niarchos Basis; Spanish Company for Worldwide Improvement Cooperation (AECID); UK Worldwide Improvement; and different personal foundations and people.
About DNDi’s sleeping illness programme
Acoziborole Winthrop is the primary oral single-dose new chemical entity to be issued from DNDi’s lead optimization programme for sleeping illness. It began with an preliminary hit recognized within the chemical library of Anacor Prescribed drugs, which was acquired by Pfizer in 2016. The preliminary construction was then optimized with Scynexis and Tempo College and was then chosen as a candidate for improvement and Part I security research performed efficiently in France, the UK, and Malaysia. Acoziborole Winthrop is the newest innovation, the results of greater than twenty years of scientific collaboration involving DNDi, Sanofi, and companions. In 2009, they developed a mixture of current medicine often known as NECT, which was extraordinarily efficient and had an excellent security profile. A donation programme was
arrange by Sanofi and Bayer to offer NECT freed from cost to endemic nations via the World Well being Group (WHO), radically enhancing remedy choices for sufferers.
DNDi, Sanofi, and companions developed fexinidazole, which in 2018 grew to become the primary all-oral remedy out there for gambiense sleeping illness. This 10-day remedy is now out there in all sleeping sickness- endemic nations.
Acoziborole Winthrop might be administered as a single oral dose, probably with out the necessity of systemic hospitalization or supervision of the remedy at residence. This implies it might turn into a significant device to facilitate efforts to lastly remove sleeping illness.
About DNDi
The Medication for Uncared for Illnesses initiative (DNDi) is a not-for-profit medical analysis group that discovers, develops, and delivers secure, efficient, and reasonably priced therapies for uncared for populations. DNDi is creating medicines for sleeping illness, leishmaniasis, Chagas illness, river blindness, mycetoma, dengue, paediatric HIV, cryptococcal meningitis, and hepatitis C. Its analysis priorities embody kids’s well being; gender fairness and gender-responsive R&D; and ailments impacted by local weather change. Since its creation in 2003, DNDi has collaborated with private and non-private companions worldwide to ship new therapies for six lethal ailments, saving tens of millions of lives. Acoziborole is the 14th remedy delivered by DNDi. dndi.org
About Sanofi
Sanofi is an R&D pushed, AI-powered biopharma firm dedicated to enhancing individuals’s lives and delivering compelling development. We apply our deep understanding of the immune system to invent medicines and vaccines that deal with and shield tens of millions of individuals world wide, with an revolutionary pipeline that may gain advantage tens of millions extra. Our crew is guided by one goal: we chase the miracles of science to enhance individuals’s lives; this evokes us to drive progress and ship optimistic influence for our individuals and the communities we serve, by addressing probably the most pressing healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
DNDi Media Relations
Frédéric Ojardias – Geneva | +41 79 431 62 16 | fojardias@dndi.org
Linet Atieno Otieno – Nairobi | +254 733 624 206| latieno@dndi.org
Ilan Moss – New York | +1 646 266 5216| imoss@dndi.org
Sanofi Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com
Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com
Sanofi Investor Relations
Thomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Nina Goworek | +1 908 569 7086 nina.goworek@sanofi.com
Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com
Further quotations from companions and supporters
UK Minister for Improvement, Jenny Chapman stated:
‘Sleeping illness is a uncared for illness which impacts a few of the poorest communities in rural Africa. It invades the central nervous system and is nearly all the time deadly with out remedy. Not so way back, the one remedy for sleeping illness was a poisonous injection with grim side-effects, so the event of a single-dose oral remedy is a historic milestone for combatting the illness. The UK’s partnership with the Medication for Uncared for Illnesses Initiative has helped ship this breakthrough, bringing the world one step nearer to eliminating sleeping illness by 2030. We’ll proceed backing world-class scientists, as a result of analysis like this protects lives world wide.’
Director Normal, Africa CDC, H.E. Dr. Jean Kaseya stated:
‘This breakthrough brings Africa nearer to eliminating sleeping illness and displays the rising power of African scientific management. The subsequent step is to make sure innovation interprets into sustainable entry for the communities most in danger. Africa CDC helps efforts to discover producing therapies like acoziborole in Africa—advancing pharmaceutical manufacturing, strengthening provide resilience, and reinforcing Africa’s well being safety, in line with Africa CDC’s drive to develop native manufacturing capability throughout the continent.’
African Union Commissioner for Well being, Humanitarian Affairs and Social Improvement, H.E. Amb. Amma Adoma Twum-Amoah stated:
‘At this time marks a historic victory for well being fairness in Africa. We’re turning what as soon as required hospital beds right into a easy treatment, eradicating the final mile boundaries to ending sleeping illness for good. This milestone proves that when world solidarity meets African management, innovation doesn’t stay in laboratories, it reaches villages, households and the very coronary heart of our communities.’
L’ambassadrice santé mondiale pour la France, Anne-Claire Amprou, a déclaré:
« La France félicite DNDi et Sanofi pour cette nouvelle étape franchie dans la lutte contre la maladie du sommeil. Fruit de l’innovation médicale, le développement de l’acoziborole, médicament révolutionnaire permettant de lutter contre cette maladie parasitaire, marque un second décisif pour protéger les communautés et sufferers situés au cœur des régions endémiques de cette maladie. Mettre l’experience scientifique française au service de la lutte contre les maladies vectorielles, notamment par la mise en œuvre de l’approche « Une seule Santé », est un axe prioritaire de la stratégie française en santé mondiale 2023 – 2027 et du One Well being Summit qui se tiendra à Lyon, le 7 avril 2026. »
Govt Director, World Well being EDCTP3, Dr Michael Makanga stated:
‘The event of acoziborole is a robust exemplar of how sustained funding in locally-led scientific analysis creates high-impact options for probably the most weak populations – right here individuals in danger of sleeping illness in all settings, even in probably the most distant communities. Constructing on the paediatric proof from the EDCTP2-funded ACOZI-KIDS mission and now the StrogHAT consortium supported by World Well being EDCTP3, evaluations are in full swing to show a one-dose oral treatment right into a sensible screen- and-treat device that may interrupt transmission and produce us nearer to eliminating gambiense human African trypanosomiasis by 2030.’
L’ambassadeur de l’Union européenne en Guinée, Xavier Sticker, a salué cette innovation :
« La lutte contre la maladie du sommeil fait aujourd’hui un nouveau pas en avant grâce à un partenariat d’acteurs de l’Equipe Europe, incluant des organisations non gouvernementales et le secteur privé. Avec l’arrivée de l’acoziborole, il suffira de prendre une seule dose pour le traitement de cette maladie endémique. Ainsi, le diagnostic et le traitement pourront être administrés conjointement et facilement sur place. En Guinée, la maladie du sommeil était un problème sanitaire majeur depuis longtemps. Grâce à une collaboration entre les companies publics, la communauté scientifique, les chercheurs et les organisations de la société civile, cette maladie a pu être reconnue il y a un an par l’Organisation mondiale de la santé comme ne constituant plus un problème de santé publique. Grâce à cette innovation européenne qu’est l’acoziborole, une étape supplémentaire pourra être franchie : la prise en cost des cas résiduels sera facilitée et toute résurgence de la maladie sera contenue, avant que l’on parvienne à son éradication complète. Cette answer européenne, validée aujourd’hui par l’EMA, est porteuse d’espoir pour la inhabitants en Guinée et au niveau mondial. L’Équipe Europe demeure un acteur fortement engagé dans le secteur de la santé en Guinée, à travers le renforcement d’un système de santé de qualité, au service de l’ensemble de la inhabitants. »
Sanofi forward-looking statements
Join free AllAfrica Newsletters
Get the newest in African information delivered straight to your inbox
This press launch accommodates forward-looking statements inside the which means of relevant securities legal guidelines, together with the Personal Securities Litigation Reform Act of 1995, as amended. Ahead-looking statements are statements that aren’t historic details. These statements embody projections and estimates and their underlying assumptions, statements concerning plans, aims, intentions, and expectations with respect to future monetary outcomes, occasions,operations, companies, product improvement and potential, and statements concerning future occasions and financial efficiency. Phrases corresponding to “count on,” “anticipate,” “consider,” “intend,” “estimate,” “plan,” “can,” “ponder,” “might,” “is designed to,” “could,” “would possibly,” “potential,” “goal,” “try,” “goal,” “mission,” “technique,” “try,” “want,” “predict,” “forecast,” “ambition,” “guideline,” “search,” “ought to,” “will,” “objective,” or the adverse of those, and related expressions are supposed to determine forward-looking statements. Though Sanofi’s administration believes that the expectations mirrored in such forward-looking statements are affordable, buyers are cautioned that forward-looking data and statements are topic to varied dangers and uncertainties, a lot of that are troublesome to foretell and customarily past the management of Sanofi, that might trigger precise outcomes and developments to vary materially from these expressed in, or implied or projected by, the ahead trying data and statements. These dangers and uncertainties embody amongst different issues, the uncertainties inherent in analysis and improvement, future scientific information and evaluation, together with submit advertising and marketing, choices by regulatory authorities, such because the U.S Meals and Drug Administration or the European Medicines Company, concerning whether or not and when to approve any drug, gadget or organic utility which may be filed for any such product candidates in addition to their choices concerning labelling and different issues that might have an effect on the provision or industrial potential of such product candidates; the truth that product candidates if authorized is probably not commercially profitable; sudden regulatory actions or delays, or authorities regulation usually; authorities’ choices concerning whether or not and when to approve a product candidate; political stress in the USA to mandate decrease drug costs together with “most favored nation” pricing for State Medicaid applications; the future approval and industrial success of therapeutic alternate options; Sanofi’s capability to learn from exterior development alternatives, to finish associated transactions and/or acquire regulatory clearances, together with future scientific information and evaluation of current scientific information regarding the product, together with submit advertising and marketing, sudden security, high quality or manufacturing points, competitors on the whole; dangers related to mental property and any associated pending or future litigation and the last word end result of such litigation; traits in alternate charges and prevailing rates of interest, risky financial and market situations, value containment initiatives and subsequent adjustments thereto, and the influence that world crises could have on us, our clients, suppliers, distributors, and different enterprise companions, and the monetary situation of any one in all them, in addition to on our staff and on the worldwide economic system as an entire. The dangers and uncertainties additionally embody the uncertainties mentioned or recognized within the public filings with the SEC and the French Markest Authority (AMF) made by Sanofi, together with these listed below “Threat Elements” and “Cautionary Assertion Relating to Ahead-Trying Statements” in Sanofi’s annual report on Type 20-F for the 12 months ended December 31, 2025 or contained in our periodic reviews on Type 6-Okay. Apart from as required by relevant legislation, Sanofi doesn’t undertake any obligation to replace or revise any forward- trying data or statements. In gentle of those dangers, uncertainties and assumptions, you shouldn’t place undue reliance on any forward-looking statements contained herein.
